Rosario Perona

List of Publications by Citations

38 papers	1,262 citations	16 h-index	35 g-index
42 ext. papers	1,379 ext. citations	6.1 avg, IF	3.83 L-index

#	Paper	IF	Citations
38	Cisplatin induces a persistent activation of JNK that is related to cell death. *Oncogene*, **1998**, 16, 533-40	9.2	210
37	Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. *Journal of Neuroscience*, **2004**, 24, 7324-34	6.6	168
36	CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. *Oncogene*, **2000**, 19, 5142-52	9.2	122
35	Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. *Angewandte Chemie - International Edition*, **2012**, 51, 10556-60	16.4	97
34	Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. *Molecular Biology of the Cell*, **2002**, 13, 2933-45	3.5	89
33	Lack of c-Jun activity increases survival to cisplatin. *FEBS Letters*, **1999**, 453, 151-8	3.8	84
32	Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. *Cancer Medicine*, **2014**, 3, 1099-111	4.8	57
31	A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. *Clinical and Translational Oncology*, **2011**, 13, 289-93	3.6	57
30	Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. *Clinical Cancer Research*, **2009**, 15, 3530-9	12.9	50
29	The role of the NFkappaB signalling pathway in cancer. *Clinical and Translational Oncology*, **2008**, 10, 143-7	3.6	46
28	Role of CHK2 in cancer development. *Clinical and Translational Oncology*, **2008**, 10, 538-42	3.6	28
27	Molecular biology of malignant gliomas. *Clinical and Translational Oncology*, **2006**, 8, 635-41	3.6	26
26	Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 91, 91-102	5.7	22
25	Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. *Clinical and Translational Oncology*, **2008**, 10, 73-7	3.6	21
24	MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. *Cancer Letters*, **2009**, 286, 206-16	9.9	19
23	A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. *Blood*, **2008**, 111, 2606-14	2.2	19
22	High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response. *Oncogenesis*, **2017**, 6, 401	6.6	16

21	Expression of the genetic suppressor element 24.2 (GSE24.2) decreases DNA damage and oxidative stress in X-linked dyskeratosis congenita cells. *PLoS ONE*, **2014**, 9, e101424	3.7	15
20	Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles. *Angewandte Chemie*, **2012**, 124, 10708-10712	3.6	14
19	GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells. *Cell Death and Differentiation*, **2019**, 26, 1998-2014	12.7	13
18	Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
17	Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain. *Clinical and Translational Oncology*, **2012**, 14, 755-63	3.6	10
16	GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dyskerin Mutant Cells. *PLoS ONE*, **2015**, 10, e0142980	3.7	9
15	Telomerase deficiency and cancer susceptibility syndromes. *Clinical and Translational Oncology*, **2009**, 11, 711-4	3.6	9
14	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 2780-2790	6.1	8
13	Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. *International Journal of Clinical and Experimental Pathology*, **2015**, 8, 2888-98	1.4	7
12	Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. *OncoImmunology*, **2020**, 9, 1773204	7.2	6
11	Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PEI-PLGA nanoparticles. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2014**, 972, 95-101	3.2	4
10	GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. *FASEB Journal*, **2021**, 35, e21422	0.9	4
9	The dual-specificity protein phosphatase MkpB, homologous to mammalian MKP phosphatases, is required for D. discoideum post-aggregative development and cisplatin response. *Differentiation*, **2011**, 81, 199-207	3.5	3
8	Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. *Clinical and Translational Oncology*, **2011**, 13, 774-9	3.6	3
7	Dyskerin Mutations Present in Dyskeratosis Congenita Patients Increase Oxidative Stress and DNA Damage Signalling in. *Cells*, **2019**, 8,	7.9	3
6	Structure of Dictyostelium discoideum telomeres. Analysis of possible replication mechanisms. *PLoS ONE*, **2019**, 14, e0222909	3.7	2
5	Molecular Diagnosis and Precision Therapeutic Approaches for Telomere Biology Disorders **2016**,		2
4	Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities.. *Cells*, **2022**, 11,	7.9	1

3	Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis.. *Immunity and Ageing*, **2022**, 19, 7	9.7	0
2	Molecular Biology of Malignant Gliomas **2009**, 1-22		
1	Choline Kinase Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. *Pharmaceutics*, **2022**, 14, 1143	6.4	